These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 15934499

  • 1. Antiangiogenic agents in cancer therapy.
    Lenz HJ.
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK.
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A, Ellis LM.
    Cancer J; 2008 Apr; 14(3):170-7. PubMed ID: 18536556
    [Abstract] [Full Text] [Related]

  • 5. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G, Sternberg C, Ferreira CG.
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [Abstract] [Full Text] [Related]

  • 6. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK.
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [Abstract] [Full Text] [Related]

  • 7. Clinical implications of antiangiogenic therapies.
    Hudis CA.
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
    [Abstract] [Full Text] [Related]

  • 8. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [Abstract] [Full Text] [Related]

  • 9. [Antiangiogenic therapy for gastrointestinal tumors].
    Lakatos G, Tulassay Z.
    Orv Hetil; 2008 Dec 07; 149(49):2317-24. PubMed ID: 19042183
    [Abstract] [Full Text] [Related]

  • 10. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
    Cézé N, Lecomte T, Watier H.
    Med Sci (Paris); 2009 Dec 07; 25(12):1099-104. PubMed ID: 20035685
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y, Liu Q.
    Adv Cancer Res; 2007 Dec 07; 97():203-24. PubMed ID: 17419947
    [Abstract] [Full Text] [Related]

  • 12. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM, LaBonte MJ, Lenz HJ.
    Cancer Chemother Pharmacol; 2013 Jan 07; 71(1):1-12. PubMed ID: 23053262
    [Abstract] [Full Text] [Related]

  • 13. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G, Longo R, Toi M, Ferrara N.
    Nat Clin Pract Oncol; 2005 Nov 07; 2(11):562-77. PubMed ID: 16270097
    [Abstract] [Full Text] [Related]

  • 14. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C.
    Clin Lung Cancer; 2008 Nov 07; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [Abstract] [Full Text] [Related]

  • 15. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ, Grossbard ML, Kozuch PS.
    Oncology (Williston Park); 2005 Mar 07; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [Abstract] [Full Text] [Related]

  • 16. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L, Hájek R, Buchler T, Maisnar V, Smolej L.
    Vnitr Lek; 2004 Dec 07; 50(12):930-8. PubMed ID: 15717808
    [Abstract] [Full Text] [Related]

  • 17. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A, Libutti SK.
    Clin Adv Hematol Oncol; 2003 Jan 07; 1(1):41-8. PubMed ID: 16227959
    [Abstract] [Full Text] [Related]

  • 18. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
    Ellis LM, Rosen L, Gordon MS.
    Clin Adv Hematol Oncol; 2006 Jan 07; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
    [Abstract] [Full Text] [Related]

  • 19. Current overview of angiogenesis inhibitors.
    Ellis LM.
    Clin Adv Hematol Oncol; 2004 Aug 07; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract] [Full Text] [Related]

  • 20. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N, Hillan KJ, Novotny W.
    Biochem Biophys Res Commun; 2005 Jul 29; 333(2):328-35. PubMed ID: 15961063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.